319 related articles for article (PubMed ID: 34459374)
1. Multi-functionalization, a Promising Adaptation to Overcome Challenges to Clinical Translation of Nanomedicines as Nano-diagnostics and Nano-therapeutics for Breast Cancer.
Moti LAA; Hussain Z; Thu HE; Khan S; Sohail M; Sarfraz RM
Curr Pharm Des; 2021; 27(43):4356-4375. PubMed ID: 34459374
[TBL] [Abstract][Full Text] [Related]
2. Nanomedicines for improved targetability to inflamed synovium for treatment of rheumatoid arthritis: Multi-functionalization as an emerging strategy to optimize therapeutic efficacy.
Fang G; Zhang Q; Pang Y; Thu HE; Hussain Z
J Control Release; 2019 Jun; 303():181-208. PubMed ID: 31015032
[TBL] [Abstract][Full Text] [Related]
3. PEGylation: a promising strategy to overcome challenges to cancer-targeted nanomedicines: a review of challenges to clinical transition and promising resolution.
Hussain Z; Khan S; Imran M; Sohail M; Shah SWA; de Matas M
Drug Deliv Transl Res; 2019 Jun; 9(3):721-734. PubMed ID: 30895453
[TBL] [Abstract][Full Text] [Related]
4. Cell membrane cloaked nanomedicines for bio-imaging and immunotherapy of cancer: Improved pharmacokinetics, cell internalization and anticancer efficacy.
Hussain Z; Rahim MA; Jan N; Shah H; Rawas-Qalaji M; Khan S; Sohail M; Thu HE; Ramli NA; Sarfraz RM; Abourehab MAS
J Control Release; 2021 Jul; 335():130-157. PubMed ID: 34015400
[TBL] [Abstract][Full Text] [Related]
5. Combining Nanomedicine and Immunotherapy.
Shi Y; Lammers T
Acc Chem Res; 2019 Jun; 52(6):1543-1554. PubMed ID: 31120725
[TBL] [Abstract][Full Text] [Related]
6. Reappraisal of anticancer nanomedicine design criteria in three types of preclinical cancer models for better clinical translation.
Luan X; Yuan H; Song Y; Hu H; Wen B; He M; Zhang H; Li Y; Li F; Shu P; Burnett JP; Truchan N; Palmisano M; Pai MP; Zhou S; Gao W; Sun D
Biomaterials; 2021 Aug; 275():120910. PubMed ID: 34144373
[TBL] [Abstract][Full Text] [Related]
7. Diethyldithiocarbamate-copper nanocomplex reinforces disulfiram chemotherapeutic efficacy through light-triggered nuclear targeting.
Ren L; Feng W; Shao J; Ma J; Xu M; Zhu BZ; Zheng N; Liu S
Theranostics; 2020; 10(14):6384-6398. PubMed ID: 32483459
[TBL] [Abstract][Full Text] [Related]
8. Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives.
Ali ES; Sharker SM; Islam MT; Khan IN; Shaw S; Rahman MA; Uddin SJ; Shill MC; Rehman S; Das N; Ahmad S; Shilpi JA; Tripathi S; Mishra SK; Mubarak MS
Semin Cancer Biol; 2021 Feb; 69():52-68. PubMed ID: 32014609
[TBL] [Abstract][Full Text] [Related]
9. The past, present, and future of breast cancer models for nanomedicine development.
Boix-Montesinos P; Soriano-Teruel PM; Armiñán A; Orzáez M; Vicent MJ
Adv Drug Deliv Rev; 2021 Jun; 173():306-330. PubMed ID: 33798642
[TBL] [Abstract][Full Text] [Related]
10. Advances of nanomedicines in breast cancer metastasis treatment targeting different metastatic stages.
Yu W; Hu C; Gao H
Adv Drug Deliv Rev; 2021 Nov; 178():113909. PubMed ID: 34352354
[TBL] [Abstract][Full Text] [Related]
11. Tumor Abnormality-Oriented Nanomedicine Design.
Zhou Q; Xiang J; Qiu N; Wang Y; Piao Y; Shao S; Tang J; Zhou Z; Shen Y
Chem Rev; 2023 Sep; 123(18):10920-10989. PubMed ID: 37713432
[TBL] [Abstract][Full Text] [Related]
12. Unraveling the role of Intralipid in suppressing off-target delivery and augmenting the therapeutic effects of anticancer nanomedicines.
Islam R; Gao S; Islam W; Šubr V; Zhou JR; Yokomizo K; Etrych T; Maeda H; Fang J
Acta Biomater; 2021 May; 126():372-383. PubMed ID: 33774199
[TBL] [Abstract][Full Text] [Related]
13. What Went Wrong with Anticancer Nanomedicine Design and How to Make It Right.
Sun D; Zhou S; Gao W
ACS Nano; 2020 Oct; 14(10):12281-12290. PubMed ID: 33021091
[TBL] [Abstract][Full Text] [Related]
14. Development of next generation nanomedicine-based approaches for the treatment of cancer: we've barely scratched the surface.
Tracey SR; Smyth P; Barelle CJ; Scott CJ
Biochem Soc Trans; 2021 Nov; 49(5):2253-2269. PubMed ID: 34709394
[TBL] [Abstract][Full Text] [Related]
15. Aptamer-guided nanomedicines for anticancer drug delivery.
Alshaer W; Hillaireau H; Fattal E
Adv Drug Deliv Rev; 2018 Sep; 134():122-137. PubMed ID: 30267743
[TBL] [Abstract][Full Text] [Related]
16. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
17. DePEGylation strategies to increase cancer nanomedicine efficacy.
Kong L; Campbell F; Kros A
Nanoscale Horiz; 2019 Mar; 4(2):378-387. PubMed ID: 32254090
[TBL] [Abstract][Full Text] [Related]
18. Recent Progress and Challenges in Clinical Translation of Nanomedicines in Diagnosis and Treatment of Lung Cancer.
Yadav B; Chauhan M; Singh RP; Sonali ; Shekhar S
Curr Drug Targets; 2024; 25(1):12-24. PubMed ID: 38058096
[TBL] [Abstract][Full Text] [Related]
19. Tumor-targeted nanomedicines for cancer theranostics.
Arranja AG; Pathak V; Lammers T; Shi Y
Pharmacol Res; 2017 Jan; 115():87-95. PubMed ID: 27865762
[TBL] [Abstract][Full Text] [Related]
20. Tumor extravasation and infiltration as barriers of nanomedicine for high efficacy: The current status and transcytosis strategy.
Zhou Q; Dong C; Fan W; Jiang H; Xiang J; Qiu N; Piao Y; Xie T; Luo Y; Li Z; Liu F; Shen Y
Biomaterials; 2020 May; 240():119902. PubMed ID: 32105817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
